Official Title
Individualized Treatments in Adults With Relapsed/Refractory Cancers
Brief Title
Individualized Treatments in Adults With Relapsed/Refractory Cancers
Protocol ID
NCT06024603
Lead Sponsor
Case Comprehensive Cancer Center
Brief Summary
A personalized cancer medicine approach would address therapy resistance, cancer
metastasis, and limited options after standard of care is exhausted in advanced cancer
participants. This approach may reduce the barriers to approved therapeutic assignment
currently limited to a particular cancer type or patient demographic.
Detailed Description
Treatment itself will not be given as part of this trial. The results of the drug
sensitivity test (DST) and genomic screening will be used to inform treating physician
about participant-specific drug sensitivity or resistance guiding best therapy choices.
The physician will decide the most appropriate treatment for each case, with the option
to add one or more personalized (assay-guided) drug(s) from the investigational platform.
All participants will need to be consented separately for any subsequent investigational
treatment if no standard treatment options are available.
Study Period
Enrollment Count
36 participants
Eligibility Criteria
Inclusion Criteria:
- Participants aged 18 years or older at the time of enrollment on this study of any
gender, race, or ethnicity.
- Patients with suspected or confirmed diagnosis of recurrent or refractory cancer
with no curative treatment options.
- Participants who have undergone at least two lines of previous therapy.
- Participants who are scheduled for or have recently had biopsy or tumor excised
(solid tumors) or bone marrow aspirate (blood cancers) or who have scheduled or
recently had paracentesis or thoracentesis performed.
- Participants willing to have a blood draw or buccal swab done for the purposes of
genetic testing.
- Participants willing to sign informed consent.
Exclusion Criteria:
- Participants who do not have malignant tissue available and accessible.
- Participants for whom the amount of excised malignant tissue is not sufficient for
the ex vivo drug testing and/or genetic profiling.
- Participants with newly diagnosed tumors and tumors that have high (>90%) cure rate
with safe standard therapy.
Filters
Refractory Cancer
Relapsed Cancer
NA
ACTIVE_NOT_RECRUITING
ADULT
OLDER_ADULT